hotspot -WSS

hotspot

author：fashion 2025-09-30 01:02:37 - browse：41

Surrounded by tablets, an elder miniature figure walks with a cane next to a stethoscope — coverage from STAT — Adobe

Medicare Advantage is arguably the most controversial health care program right now — a sentiment that was bolstered Friday by striking new data about overpayments and an uncommon political jab during a routine meeting of policy wonks.

The Medicare Payment Advisory Commission, a group that advises Congress on Medicare policy, gathered to discuss its pending March report on the state of Medicare Advantage, the alternative to traditional Medicare that is run by health insurance companies. Medicare Advantage is expected to cost taxpayers $507 billion this year, according to the latest federal estimates.

The group, known as MedPAC, came to several familiar conclusions from the staff’s presentation and report: The federal government significantly overpays Medicare Advantage insurers because they attract healthier, lower-cost people into their plans and then excessively code those people’s health conditions — making Medicare Advantage a drain on taxpayers. MedPAC’s staffers also reiterated that Medicare Advantage’s quality rating system is “not a good basis for judging quality,” and therefore leads to further overpayments because insurers are paid bonuses based on this quality system.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： CRISPR pioneers react to Casgevy, first gene

focus

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Readout LOUD podcast: A CRISPR milestone, biotech mixology

World's first CRISPR

Sana to lay off nearly a third of staff, de

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

hotspot

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Astellas still sees hope in its gene therapy after four deaths

How to save PrEP access — and even expand it

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

The cancer drug shortage isn’t new — and neither are the solutions

VC firm General Catalyst wants to buy a health system

Walensky prepares to leave CDC — and Congress — behind

Poor hospice wound care hurts patients and families

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: A CRISPR milestone, biotech mixology

explore

Chan Zuckerberg Biohub Chicago to focus on inflammation

Chan Zuckerberg Biohub Chicago to focus on inflammation

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

World's first CRISPR

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA authorizes Novavax’s updated Covid

knowledge

entertainment

focus

leisure time